The WHO update recommends that methylome profiling may also be used as a surrogate marker when a methylome signature is characteristic of an IDH-wildtype glioblastoma in the absence of IDH mutation testing—but it cannot serve as a surrogate when targeted therapies and clinical trials require the demonstration of specific mutations before patient treatment [4]. This evidence concerns the gene IDH1 and glioblastoma.